

A Message to the Patient Community About Cogent's Expanded Access Programs

At Cogent Biosciences, we understand how difficult it can be to face a rare disease or cancer, especially when standard treatments are no longer effective and clinical trials are not an option. In these moments, patients and their families may begin to explore other possibilities, including access to investigational therapies.

If an appropriate clinical trial isn't available, your doctor may be able to request access to an investigational therapy through a mechanism sometimes called compassionate use or expanded access. At Cogent, we currently have Expanded Access Programs for eligible patients in the United States with Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST).

How the Cogent Expanded Access Process Works:

- Only your doctor can submit a request for expanded access to Cogent's investigational therapy on your behalf
- Your doctor can review our policy and submit a request by visiting:
<https://www.cogentbio.com/bezuclastinib-program-development/#our-expanded-access-policy>
- Our medical team will carefully evaluate each request based on the available scientific data, the nature of the condition, and the potential risks and benefits
- If approved, Cogent will communicate with your doctor on next steps

We are committed to transparency, compassion, and timely communication throughout this process. Our team works closely with doctors to ensure that every request is handled with care and urgency. Everything we communicate to your doctor—our decisions and the information we provide—will reflect the current scientific evidence available to us about the investigational treatment.

Share This Letter with Your Doctor:

If you are considering expanded access, we encourage you to download this letter and bring it to your next appointment or share it directly with your doctor via your patient portal. It can help guide the conversation with your care team about available clinical trials and treatment options.

Warm regards,
The Cogent Biosciences Team